TITLE

Atorvastatin at 80 mg/d reduced major cardiovascular events more than atorvastatin at 10 mg/d in stable coronary heart disease

AUTHOR(S)
Davidson, Michael H.
PUB. DATE
September 2005
SOURCE
ACP Journal Club;Sep/Oct2005, Vol. 143 Issue 2, p38
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents an answer to a clinical question related to the comparison of the effectiveness of intensive atorvastatin therapy in patients with coronary heart disease (CHD), with moderate atorvastatin therapy for reducing major cardiovascular events. This study included 10,001 patients 35 to 75 years of age who had clinically evident CHD and low-density lipoprotein. Exclusion criteria included hypersensitivity to statins, active liver disease, pregnancy, and uncontrolled diabetes mellitus.
ACCESSION #
18427109

 

Related Articles

  • Bivalirudin costs made out in ACUITY.  // PharmacoEconomics & Outcomes News;4/5/2008, Issue 550, p8 

    The article discusses research on the cost attraction of bivalirudin monotherapy which is shown to be as effective as standard therapy in the treatment of patients with acute coronary syndromes. It references a study by D. S. Pinto et al presented at the Annual Scientific Session of the American...

  • Strategies for raising HDL cholesterol levels. Bersot, Thomas P.; Gregory, Tanya // Patient Care;1/15/2000, Vol. 34 Issue 1, p151 

    Presents several measures for increasing the high density lipoprotein (HDL) cholesterol levels of cardiac patients. Cardioprotective effect of HDL; Factors affecting HDL levels; Drug therapies for increasing HDL levels.

  • Rational approaches to the treatment of mixed dyslipidemia.  // Formulary;Oct2008, Vol. 43 Issue 10, p366 

    The article reports on the treatment of patients with coronary heart diseases, including mixed dyslipidemia. According to the author, using optimal statin therapy in targeting low-density lipoprotein (LDL) is an accepted treatment for the disease. However, the author says that combination...

  • Aspirin Combined With Clopidogrel (Plavix) Decreases Cardiovascular Events in Patients with Acute Coronary Syndrome. Walker, Christopher W.; Dawley, Courtney A.; Fletcher, Stacy F. // American Family Physician;12/1/2007, Vol. 76 Issue 11, p1643 

    The article focuses on the effectiveness of the combination of aspirin with clopidogrel in treating patients with a high risk of cardiovascular disease or patients with acute coronary syndrome. It notes that clopidogrel improves outcomes in patients with coronary artery stent replacement....

  • Ischemic Heart Disease.  // Current Medical Literature: Cardiology;2006, Vol. 25 Issue 1, p23 

    The article focuses on the outcome of a study that compared an early invasive strategy (EIS) and a selectively invasive strategy (SIS) in the management of acute coronary syndromes in patients receiving aggressive medical therapy. Several drugs were initially given to the study participants. The...

  • Opening a New Lipid "Apo-thecary": Incorporating Apohpoprotezns as Potential Risk Factors and Treatment Targets to Reduce Cardiovascular Risk. JACOBSON, TERRY A. // Mayo Clinic Proceedings;Aug2011, Vol. 86 Issue 8, p762 

    Statins (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors) represent the cornerstone of drug therapy to reduce low-density lipoprotein (LDL) cholesterol and cardiovascular risk. However, even optimal statin management of LDL cholesterol leaves many patients with residual cardiovascular...

  • Dual Antithrombotic Therapy's Increased Risks Not Always Offset by Benefit. Mitka, Mike // JAMA: Journal of the American Medical Association;10/3/2007, Vol. 298 Issue 13, p1504 

    This article reports on research into dual versus monotherapy in cardiovascular disease patients. Evidence seems to be suggesting that dual anticoagulation and antiplatelet therapy isn't any more effective than treatment with an anticoagulant alone and it may even increase the risk of...

  • Clinical utility of ivabradine in cardiovascular disease management: current status. Rosano, Giuseppe M. C.; Vitale, Cristiana; Spoletini, Ilaria; Volterrani, Maurizio // Research Reports in Clinical Cardiology;2014, Vol. 5, p183 

    Ivabradine is a selective antagonist of the funny channels with anti-anginal and antiischemic properties, approved for the treatment of coronary artery disease (CAD) and heart failure (HF). It provides pure heart rate reduction, reducing the diastolic depolarization slope, without altering...

  • Conventional and Novel Drug Therapeutics to Relief Myocardial Ischemia. Dvir, Danny; Battler, Alexander // Cardiovascular Drugs & Therapy;Aug2010, Vol. 24 Issue 4, p319 

    Effective management of stable angina usually includes drug therapy. There are several agents that are considered vasculoprotective such as aspirin, angiotensin converting enzyme inhibitors and statins. Conventional anti ischemic therapy includes nitrates, beta-blockers and calcium-channel...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics